Clinical Trial Update: Do HMG CoA Reductase Inhibitors Affect Abeta Levels? [Phase 4]

View source ↗

Summary

Phase 4 trial evaluated whether HMG-CoA reductase inhibitors affect Abeta levels in Alzheimer's disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Statins (HMG-CoA reductase inhibitors) (statin)

Snippet

Sponsor: Seattle Institute for Biomedical and Clinical Research | Conditions: Alzheimer's Disease, Aging | Phase 4 | Status: COMPLETED